Neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax.
Edema factor (EF) is a component of an anthrax toxin that functions as an adenylate cyclase. Numerous monoclonal antibodies (MAbs) have been reported for the other Bacillus anthracis toxin components, but relatively few to EF have been studied. We report the generation of six murine hybridoma lines producing two IgM and four IgG1 MAbs to EF. Of the six MAbs, only one IgM neutralized EF, as assayed by an increase in cyclic AMP (cAMP) production by Chinese hamster ovary (CHO) cells. Analysis of the variable gene elements revealed that the single neutralizing MAb had a different binding site than the others. There was no competition between the neutralizing IgM and the nonneutralizing IgG MAbs indicative of different specificity. MAb-based capture enzyme-linked immunosorbent assay (ELISA) detected EF in liver lysates from mice infected with B. anthracis Sterne 34F2. Administration of the neutralizing IgM MAb to A/JCr mice lethally infected with B. anthracis strain Sterne had no significant effect on median time to death, but mice treated with the MAb were more likely to survive infection. Combining the neutralizing IgM to EF with a subprotective dose of a neutralizing MAb to protective antigen (PA) prolonged mean time to death of infected mice, suggesting that neutralization of EF and PA could produce synergistic beneficial effects. In summary, the results from our study and literature observations suggest that the majority of Abs to EF are nonneutralizing, but the toxin has some epitopes that can be targeted by the humoral response to generate useful Abs that may contribute to defense against anthrax.
Winterroth
Lisa
L
Departments of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA.
Rivera
Johanna
J
Nakouzi
Antonio S
AS
Dadachova
Ekaterina
E
Casadevall
Arturo
A
D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000473:pathology* / Q000517:prevention & control; D000907:Antibodies, Bacterial / Q000276:immunology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000633:toxicity; D000992:Antitoxins / Q000276:immunology* / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors* / Q000633:toxicity; D001665:Binding Sites; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D005260:Female; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D011485:Protein Binding; D016019:Survival Analysis
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D000992:Antitoxins; D001427:Bacterial Toxins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; C030325:anthrax toxin
J Immunol. 2007 Aug 15;179(4):2419-27
17675503
J Mol Biol. 2008 May 16;378(5):1094-103
18423488
J Biol Chem. 1981 May 25;256(10):5116-20
6262318
Immunogenetics. 1992;36(5):306-13
1644448
Biochem Biophys Res Commun. 1994 Mar 15;199(2):676-82
8135809
Eur J Immunol. 1999 Jul;29(7):2082-6
10427970
Clin Vaccine Immunol. 2008 Jan;15(1):71-5
18032590
Hematol Oncol. 1995 Jul-Aug;13(4):185-200
7557895
Cell Microbiol. 2003 Jan;5(1):15-23
12542467
Infect Immun. 2005 Oct;73(10):6547-51
16177329
Infect Immun. 1997 Dec;65(12):5171-5
9393812
Antimicrob Agents Chemother. 2009 Nov;53(11):4860-8
19704133
Antimicrob Agents Chemother. 2007 Aug;51(8):2758-64
17517846
Proc Natl Acad Sci U S A. 1982 May;79(10):3162-6
6285339
JAMA. 2002 May 1;287(17):2236-52
11980524
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13487-92
19651602
Infect Immun. 2006 Mar;74(3):1500-4
16495520
Expert Opin Drug Deliv. 2005 Nov;2(6):1075-84
16296810
Infect Immun. 2006 Jul;74(7):4149-56
16790789
Nucl Med Biol. 2008 Oct;35(7):755-61
18848660
Nature. 1980 Aug 14;286(5774):676-83
6774258
J Immunol. 2003 Apr 1;170(7):3621-30
12646626
Annu Rev Cell Dev Biol. 2003;19:45-70
14570563
AIDS. 1988 Dec;2(6):465-72
3149493
J Immunol Methods. 1980;35(1-2):1-21
7009747
Eur J Immunol. 1986 Jul;16(7):871-4
3487461
Am J Pathol. 2005 Nov;167(5):1309-20
16251415
Infect Immun. 2004 Nov;72(11):6313-7
15501759
J Immunol. 1999 Feb 1;162(3):1541-50
9973411
Clin Exp Immunol. 1991 Apr;84(1):1-8
1707767
Nat Biotechnol. 2002 Jun;20(6):597-601
12042864
Mol Immunol. 2001 Jan;38(1):9-18
11483206
Infect Immun. 2007 Nov;75(11):5443-52
17709410
Proc Natl Acad Sci U S A. 1987 Apr;84(8):2454-8
3104915
BMC Microbiol. 2008 Sep 23;8:159
18811967
Infect Immun. 1994 Mar;62(3):1079-88
8112842
Eur J Immunol. 1988 Feb;18(2):313-6
3350037
Infect Immun. 2007 May;75(5):2120-5
17339348
J Immunol Methods. 1992 Sep 18;154(1):27-35
1401941
Infect Immun. 2006 May;74(5):3042-5
16622248
Hum Antibodies. 2005;14(1-2):33-55
16424599